<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666484</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000593560</org_study_id>
    <secondary_id>UCL/07/005</secondary_id>
    <secondary_id>2007-003080-45</secondary_id>
    <secondary_id>EU-20844</secondary_id>
    <nct_id>NCT00666484</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma</brief_title>
  <official_title>Phase II Study Evaluating the Toxicity and Efficacy of a Modified German Paediatric Hodgkin's Lymphoma Protocol (HD95) in Young Adults (Aged 18-30 Years) With Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer
      cells, either by killing the cells or by stopping them from dividing. It is not yet known
      which regimen of combination chemotherapy is more effective for Hodgkin lymphoma.

      PURPOSE: This phase II trial is studying the side effects of three different regimens of
      combination chemotherapy and to see how well they work in treating younger patients with
      Hodgkin lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To establish neurotoxicity of OEPA+COPP chemotherapy in young adults.

      Secondary

        -  To determine response rates in patients treated with this regimen.

        -  To determine disease-free survival of patients treated with this regimen.

        -  To determine overall survival of patients treated with this regimen.

        -  To determine gonadal toxicity in patients treated with this regimen.

      OUTLINE: Patients are assigned to treatment group according to stage.

        -  Group 1 (patients with stage 1A, 1B, or 2A disease): Patients receive OEPA chemotherapy
           comprising vincristine IV on days 1, 8, and 15; oral prednisolone on days 1-15;
           etoposide IV on days 1-5; and doxorubicin hydrochloride IV on days 1 and 15. Courses
           repeat every 28 days for 2 courses. Patients achieving a partial response also undergo
           radiotherapy after completion of chemotherapy; patients achieving a complete response do
           not undergo radiotherapy.

        -  Group 2 (patients with stage 2AE, 2B, or 3A disease): Patients receive 2 courses of OEPA
           chemotherapy as in group 1. Patients then receive COPP chemotherapy comprising
           cyclophosphamide IV on days 1 and 8; vincristine IV on days 1 and 8; oral procarbazine
           hydrochloride on days 1-15; and oral prednisolone on days 1-15. Courses repeat every 28
           days for 2 courses. Patients also undergo radiotherapy after completion of chemotherapy.

        -  Group 3 (patients with stage 2BE, 3AE, 3BE, 3B, 4A, or 4B disease): Patients receive 2
           courses of OEPA chemotherapy as in group 1. Patients then receive COPP chemotherapy as
           in group 2. Treatment with COPP chemotherapy repeats every 28 days for 4 courses.
           Patients also undergo radiotherapy after completion of chemotherapy.

      In all groups, treatment continues in the absence of disease progression or unacceptable
      toxicity.

      After completion of study therapy, patients are followed periodically.

      Peer Reviewed and Funded or Endorsed by Cancer Research UK.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurotoxicity due to the intensive use of Vinca alkaloids</measure>
    <time_frame>End of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>End of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Not specified in protocol</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Not specified in protocol</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gonadal toxicity</measure>
    <time_frame>Not specified in protocol</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Lymphoma</condition>
  <condition>Neurotoxicity</condition>
  <arm_group>
    <arm_group_label>Treatment Group 1: stages 1A, 1B, 2A: OEPA x 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OEPA (28day cycle):
Vincristine 1.5mg/m^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m^2 iv d1-5 Prednisolone 60mg/m^2 po d1-15 Adriamycin 40mg/m^2 iv d1 and 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 2: stages 2AE, 2B, 3A: OEPA x 2 + COPP x 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OEPA (28 day cycle) Vincristine 1.5mg/m^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m^2 iv d1-5 Prednisolone 60mg/m^2 po d1-15 Adriamycin 40mg/m^2 iv d1 and 15
COPP (28 day cycle) Cyclophosphamide 500mg/m^2 iv d1 and 8 Vincristine 1.5mg/m^2 iv d1,8 (capped 2mg/dose) Procarbazine 100mg/m^2 po d1-15* Prednisolone 40mg/m^2 po d1-15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 3: stages 2BE, 3AE, 3B, 4: OEPAx2 + COPPx4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OEPA (28 day cycle) Vincristine 1.5mg/m^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m^2 iv d1-5 Prednisolone 60mg/m^2 po d1-15 Adriamycin 40mg/m^2 iv d1 and 15
COPP (28 day cycle) Cyclophosphamide 500mg/m^2 iv d1 and 8 Vincristine 1.5mg/m^2 iv d1,8 (capped 2mg/dose) Procarbazine 100mg/m^2 po d1-15* Prednisolone 40mg/m^2 po d1-15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Treatment Group 2: stages 2AE, 2B, 3A: OEPA x 2 + COPP x 2</arm_group_label>
    <arm_group_label>Treatment Group 3: stages 2BE, 3AE, 3B, 4: OEPAx2 + COPPx4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Treatment Group 1: stages 1A, 1B, 2A: OEPA x 2</arm_group_label>
    <arm_group_label>Treatment Group 2: stages 2AE, 2B, 3A: OEPA x 2 + COPP x 2</arm_group_label>
    <arm_group_label>Treatment Group 3: stages 2BE, 3AE, 3B, 4: OEPAx2 + COPPx4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <arm_group_label>Treatment Group 1: stages 1A, 1B, 2A: OEPA x 2</arm_group_label>
    <arm_group_label>Treatment Group 2: stages 2AE, 2B, 3A: OEPA x 2 + COPP x 2</arm_group_label>
    <arm_group_label>Treatment Group 3: stages 2BE, 3AE, 3B, 4: OEPAx2 + COPPx4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
    <arm_group_label>Treatment Group 1: stages 1A, 1B, 2A: OEPA x 2</arm_group_label>
    <arm_group_label>Treatment Group 2: stages 2AE, 2B, 3A: OEPA x 2 + COPP x 2</arm_group_label>
    <arm_group_label>Treatment Group 3: stages 2BE, 3AE, 3B, 4: OEPAx2 + COPPx4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>procarbazine hydrochloride</intervention_name>
    <arm_group_label>Treatment Group 2: stages 2AE, 2B, 3A: OEPA x 2 + COPP x 2</arm_group_label>
    <arm_group_label>Treatment Group 3: stages 2BE, 3AE, 3B, 4: OEPAx2 + COPPx4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>Treatment Group 1: stages 1A, 1B, 2A: OEPA x 2</arm_group_label>
    <arm_group_label>Treatment Group 2: stages 2AE, 2B, 3A: OEPA x 2 + COPP x 2</arm_group_label>
    <arm_group_label>Treatment Group 3: stages 2BE, 3AE, 3B, 4: OEPAx2 + COPPx4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Treatment Group 1: stages 1A, 1B, 2A: OEPA x 2</arm_group_label>
    <arm_group_label>Treatment Group 2: stages 2AE, 2B, 3A: OEPA x 2 + COPP x 2</arm_group_label>
    <arm_group_label>Treatment Group 3: stages 2BE, 3AE, 3B, 4: OEPAx2 + COPPx4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Biopsy proven de-novo classical Hodgkin lymphoma

               -  Any stage disease

               -  No nodular lymphocyte-predominant Hodgkin lymphoma

        PATIENT CHARACTERISTICS:

          -  No known or suspected HIV infection

          -  No pre-existing neurological disorder

          -  No serious comorbidity which may prevent administration of study treatment

          -  No other previous malignancy

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for up to 1 year after
             completion of study treatment

          -  Creatinine ≤ 1.5 times upper limit of normal (ULN) unless due to the lymphoma

          -  ALT/AST ≤ 1.5 times ULN unless due to the lymphoma

          -  Bilirubin ≤ 2 times ULN unless due to the lymphoma

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or radiotherapy

          -  No prior organ transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirit Ardeshna</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College London Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital - London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Centre for Cancer Treatment at Newcastle General Hospital</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre at Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <state>England</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2008</study_first_posted>
  <last_update_submitted>December 3, 2014</last_update_submitted>
  <last_update_submitted_qc>December 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neurotoxicity</keyword>
  <keyword>stage I adult Hodgkin lymphoma</keyword>
  <keyword>stage II adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>adult lymphocyte depletion Hodgkin lymphoma</keyword>
  <keyword>adult lymphocyte predominant Hodgkin lymphoma</keyword>
  <keyword>adult mixed cellularity Hodgkin lymphoma</keyword>
  <keyword>adult nodular sclerosis Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

